Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study
Authors:
- Cornelia NitipirCNCornelia Nitipir
- Radu VrabieRVRadu Vrabie
- Andreea Ioana ParosanuAPAndreea Ioana Parosanu
- Raluca TulinRTRaluca Tulin
- Bogdan CretuBCBogdan Cretu
- Adrian CursaruACAdrian Cursaru
- Iulian SlavuISIulian Slavu
- Adrian MironAMAdrian Miron
- Valentin CaluValentin Calu
- Maria Cristina Orlov SlavuMSMaria Cristina Orlov Slavu
Open Access
- 8 November 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Abstract
Although a toxic regimen, FOLFIRINOX is one of the most efficient chemotherapy regimens in advanced pancreatic adenocarcinoma. There is no standard number of cycles in locally advanced or metastatic stages. The present retrospective study reports the experience of a single center with this regimen administered until disease progression or unacceptable toxicity. The authors of this retrospective study analyzed the data on patients with this diagnosis treated in our clinic during 2017-2021. Forty-two patients were included in the study, 21 who received six courses or less and 21 who received more than six courses. Progression-free survival (PFS) and overall survival (OS) were analyzed according to this stratification. The oncological response was also reported according to dose reduction and treatment delay, irrespective of the number of courses administered. Median PFS was 7.5 months, and median OS was 13.6 months in the entire studied population. When patients were compared according to the number of courses received (under six vs. over six), there were obvious differences (PFS: 5.17 months vs. 11.2, p = 0.8, OS: 8 months vs. 17.3 months, p = 0.6). However, when stratifying survival by treatment delay and the presence or absence of dose reduction, better results were seen with lower doses (p<0.001) and treatment temporization (p=0.03). The general incidence of hematologic and neurologic toxicity was higher than the ones reported in the literature. The study revealed that patients benefit from the administration of FOLFIRINOX for more than six months, but that the administration of full dose and the maintaining dose intensity does not necessarily favor the patient.Keywords
This publication has 16 references indexed in Scilit:
- FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experienceBritish Journal of Cancer, 2016
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOXOncology, 2016
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerBritish Journal of Cancer, 2016
- Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre ExperienceOncology, 2015
- FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden ExperienceClinical Colorectal Cancer, 2014
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic AdenocarcinomaPancreas, 2013
- FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicityMedical Oncology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Advanced pancreatic carcinoma: current treatment and future challengesNature Reviews Clinical Oncology, 2010